MBIO

Mustang Bio is a clinical-stage cancer biotech with zero product revenue in any year shown and, in its own words, does 'not expect to generate any revenues from product sales in the foreseeable future, if ever.' The entire pipeline — MB-101 CAR-T, MB-108 oncolytic virus, and the MB-109 combination — sits at Phase 1, and the lead-in trials have merely 'completed the treatment phase' with patients still in long-term safety follow-up. There is no approved product and no near-term path to one. The $399M accumulated deficit against just $9.53M of equity tells you how much capital has been consumed to get here.

The headline that net loss 'improved' 87.8% to -$1.92M is a contraction story, not a progress story. Management terminated the lease on its Worcester, MA cell-processing center and is now exploring whether MB-109 can run as a low-cost 'investigator-sponsored single-institution study' at City of Hope in Q2 2026 — a downshift from a company-run multicenter trial to leaning on an academic partner. Operating cash flow was still -$5.26M; on $17.3M of cash that is only a few years of runway, and the filing explicitly warns there is 'no assurance that we will be successful in securing additional resources when needed, on terms acceptable to us, if at all.'